{{Rsnum
|rsid=4078023
|Gene=GP2
|Chromosome=16
|position=20308765
|Orientation=minus
|GMAF=0.07025
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 96.5 | 3.5 | 0.0
| HCB | 78.7 | 20.6 | 0.7
| JPT | 69.0 | 27.4 | 3.5
| YRI | 93.8 | 6.2 | 0.0
| ASW | 98.2 | 1.8 | 0.0
| CHB | 78.7 | 20.6 | 0.7
| CHD | 87.2 | 12.8 | 0.0
| GIH | 91.1 | 8.9 | 0.0
| LWK | 95.5 | 3.6 | 0.9
| MEX | 65.5 | 32.8 | 1.7
| MKK | 93.5 | 4.5 | 1.9
| TSI | 96.1 | 3.9 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4078023
|Name_s=
|Gene_s=GP2
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.04, combined P value= 2.79E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470225
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4078023
|overall_frequency_n=121
|overall_frequency_d=128
|overall_frequency=0.945312
|n_genomes=54
|n_genomes_annotated=0
|n_haplomes=103
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}